122
Participants
Start Date
August 12, 2020
Primary Completion Date
August 31, 2026
Study Completion Date
October 31, 2026
AMXI-5001:Dose Escalation Phase I
Phase I will enroll up to 70 participants to identify the Recommended Phase II daily dose in the treatment of various cancers and to characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
AMXI-5001:Dose Expansion Phase II
Phase II will enroll up to 52 study participants to further characterize the safety, pharmacology, and clinical efficacy of AMXI-5001. AMXI-5001 is administered orally twice daily, with food. AMXI-5001 is administered weekly on a continuous 7-day schedule. Each cycle is 28 days.
RECRUITING
Johns Hopkins, Baltimore
RECRUITING
SCRI Oncology Partners, Nashville
RECRUITING
The University of Texas MD Anderson Cancer Center, Houston
RECRUITING
University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles
AtlasMedx, Incorporated
INDUSTRY